These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29220430)

  • 21. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: a retrospective chart review.
    Do P; Andersen J; Patel A; Semrin G; Sifuentes-Dominguez L; Luu P; Gurram B
    F1000Res; 2020; 9():316. PubMed ID: 34504690
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
    Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
    Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery.
    Kasparek MS; Bruckmeier A; Beigel F; Müller MH; Brand S; Mansmann U; Jauch KW; Ochsenkühn T; Kreis ME
    Inflamm Bowel Dis; 2012 Jul; 18(7):1207-13. PubMed ID: 21928373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
    Axelrad JE; Li T; Bachour SP; Nakamura TI; Shah R; Sachs MC; Chang S; Hudesman DP; Holubar SD; Lightner AL; Barnes EL; Cohen BL; Rieder F; Esen E; Remzi F; Regueiro M; Click B
    Inflamm Bowel Dis; 2023 Jun; 29(6):888-897. PubMed ID: 35905032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.
    Yu CS; Jung SW; Lee JL; Lim SB; Park IJ; Yoon YS; Kim CW; Yang SK; Ye BD; Park SH; Han M; Kim JC
    Inflamm Bowel Dis; 2019 Aug; 25(9):1559-1568. PubMed ID: 30753560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis.
    Lightner AL; McKenna NP; Moncrief S; Pemberton JH; Raffals LE; Mathis KL
    Inflamm Bowel Dis; 2017 Dec; 23(12):2197-2201. PubMed ID: 28858072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab versus ustekinumab in Crohn's disease with prior anti-tumor necrosis factor failure: an updated meta-analysis.
    Milioli NJ; Fernandes MV; Correa TL; Antunes V; Martins OC; Florêncio de Mesquita C; Baraldo S; Furfaro F
    Eur J Gastroenterol Hepatol; 2024 Sep; 36(9):1068-1074. PubMed ID: 38973525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease.
    Kotze PG; Saab MP; Saab B; da Silva Kotze LM; Olandoski M; Pinheiro LV; Martinez CA; Ayrizono ML; Magro DO; Coy CS
    Dig Dis Sci; 2017 Feb; 62(2):456-464. PubMed ID: 27933472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy.
    Cullen G; Vaughn B; Ahmed A; Peppercorn MA; Smith MP; Moss AC; Cheifetz AS
    Inflamm Bowel Dis; 2012 Apr; 18(4):691-6. PubMed ID: 21648022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
    Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T
    J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients.
    Murate K; Maeda K; Nakamura M; Sugiyama D; Wada H; Yamamura T; Sawada T; Mizutani Y; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Miyahara R; Ishigami M; Nishikawa H; Fujishiro M
    Inflamm Bowel Dis; 2020 Oct; 26(11):1669-1681. PubMed ID: 32405651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
    Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
    J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients.
    Lightner AL; Grass F; Alsughayer AM; Harmsen WS; Petersen M; Loftus EV
    Dis Colon Rectum; 2020 Jul; 63(7):934-943. PubMed ID: 32149787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Readmission After Abdominal Surgery for Crohn's Disease: Identification of High-Risk Patients.
    Mege D; Michelassi F
    J Gastrointest Surg; 2018 Sep; 22(9):1585-1592. PubMed ID: 29770917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.